Targeting B Cells in Lupus: Efforts Persist

Atacicept showed benefits in lupus patients with high levels of two B-cell biomarkers, a Phase III study found, suggesting the potential for more personalized treatment of lupus.

EULAR Recommends Exercise First For Fibromyalgia

Exercise should be considered as the first option for treatment of fibromyalgia, according to updated recommendations from the European League Against Rheumatism (EULAR).

FDA Panel Backs Psoriasis Drug With Caveats

Valeant Pharmaceuticals’ experimental psoriasis drug brodalumab has been recommended for approval by an advisory committee to the FDA, providing that certain measures are taken to reduce the risk of suicide in patients who take it.

Zapping RA: Electrical Stimulation as Novel Treatment?

First study of its kind evaluates nerve stimulation as a potential rheumatoid arthritis treatment.

FDA Panel Backs Biosimilar for Humira

An advisory panel to the FDA has recommended that the biosimilar for AbbVie’s top-selling arthritis drug Humira (adalimumab) be approved, but a patent dispute could delay its availability.

FDA Staff: Sandoz’s Enbrel Biosimilar is ‘Highly Similar’ to Amgen’s Blockbuster

The FDA has concluded that Sandoz’s biosimilar GP2015 and Amgen’s blockbuster Enbrel (etanercept) are “highly similar,” another good sign for the U.S. biosimilars market.

RA Survival Rates Outpacing that of General Population

Have survival rates improved for rheumatoid arthritis patients? Researchers say yes, thanks to advances in drug development and management strategies over the past 15 years.

LDL Increase with Tofacitinib: Does it Matter?

Despite increases in low-density lipoprotein (LDL) cholesterol, the rate of cardiovascular events in patients treated with tofacitinib (Xeljanz) for rheumatoid arthritis (RA) is low, Pfizer-sponsored research shows.

Cancer May Predispose to IgG4-Related Disease

A new study shows that a history of invasive malignancy appears to be associated with later development of immunoglobulin G4-related disease.

Outlook Brightens in Systemic Juvenile Rheumatoid Arthritis

Outcomes have improved significantly since the year 2000 for those with systemic juvenile idiopathic arthritis, German researchers reported.

Join CreakyJoints, a community of people with all forms of arthritisSign Up